1 Pal C.Antigen trapping by dendritic cells for antitumor therapy[J].Methods Mol Biol,2014,1139(6):33-40. 2 Ackerman AL,Cresswell P.Cellular mechanisms governing cross presentation of exogenous antigens[J].Nat Immunol,2004,5(7):678-684. 3 Tacken PJ,Torensma R,Figdor CG.Targeting antigens to dendritic cells in vivo[J].Immunobiology,2006,211(6-8):599-608. 4 Lim S,Koo JH,Choi JM.Use of cell-penetrating peptides in dendritic cell-based vaccination[J].Immune Netw,2016,16(1):33-43. 5 Radej S,Roliński J,Rawicz-Pruszyński K,et al.Immunomodelling characteristics of mature dendritic cells stimulated by colon cancer cells lysates[J].Pol Przegl Chir,2015,87(2):71-82. 6 Aarntzen EH,Srinivas M,De Wilt JH,et al.Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3′-fluoro-3′-deoxy-thymidine([18F]FLT)PET imaging[J].Proc Natl Acad Sci U S A,2011,108(45):18396-18399. 7 Sui CG,Wu D,Meng FD,et al.Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells:an immunotherapy study[J].Genet Mol Res,2015,14(2):7208-7217. 8 Gulubova MV,Ananiev JR,Vlaykova TI,et al.Role of dendritic cells in progression and clinical outcome of colon cancer[J].Int J Colorectal Dis,2012,27(2):159-169. 9 Okada H,Kalinski P,Ueda R,et al.Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma[J].J Clin Oncol,2011,29(3):330-336. 10 Hobo W,Strobbe L,Maas F,et al.Immunogenicity of dendritic cells pulsed with MAGE3,Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients[J].Cancer Immunol Immunother,2013,62(8):1381-1392. 11 Wang RF,Wang HY.Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells[J].Nat Biotechnol,2002,20(2):149-154. 12 Kronenberg K,Brosch S,Butsch F,et al.Vaccination with TAT-antigen fusion protein induces protective,CD8(+)T cell-mediated immunity against Leishmania major[J].J Invest Dermatol,2010,130(11):2602-2610. 13 Allard SD,De Keersmaecker B,de Goede AL,et al.A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat,Rev and Nef expressing dendritic cells followed by treatment interruption[J].Clin Immunol,2012,142(3):252-268. 14 Park JS,Park SY,Cho HI,et al.Enhanced induction of T cell immunity using dendritic cells pulsed with HIV tat and HCMV-pp65 fusion protein in vitro[J].Immune Netw,2011,11(3):182-189. 15 Pouniotis DS,Esparon S,Apostolopoulos V,et al.Whole protein and defined CD8(+)and CD4(+)peptides linked to penetratin targets both MHC class I and II antigen presentation pathways[J].Immunol Cell Biol,2011,89(8):904-913. 16 Derouazi M,Di Berardino-Besson W,Belnoue E,et al.Novel cell-penetrating peptide-based vaccine induces robust CD4+and CD8+T cell-mediated antitumor immunity[J].Cancer Res,2015,75(15):3020-3031. 17 Meloni BP,Milani D,Edwards AB,et al.Neuroprotective peptides fused to arginine-rich cell penetrating peptides:Neuroprotective mechanism likely mediated by peptide endocytic properties[J].Pharmacol Ther,2015,153(6):36-54. |